As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Antimicrobial Resistance (AMR) poses a significant threat to global healthcare systems and patient safety
The group now has 372 approvals and has so far filed over 442* ANDAs since the commencement of the filing process in FY 2003-04.
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
The oCelloscope technology is a unique live-cell imaging system for sensitive and detailed monitoring of biological growth and development
Leading Research-driven Pharma Company Combats Antibiotic Resistance and Demonstrates Innovation in Medical Solutions
The additional $50 million will go towards venture capital firms that specialize in near- and long-term healthcare solutions for patients in low- and middle-income countries
Specialty Chemicals grew 38% YoY for FY23
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Subscribe To Our Newsletter & Stay Updated
